Published in Int Rev Immunol on February 01, 2012
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) | NCT00092534
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein. Clin Vaccine Immunol (2013) 0.78
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med (1999) 9.16
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med (1999) 7.56
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med (2007) 3.77
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol (1999) 3.50
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2005) 2.94
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell (2004) 2.46
Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 2.37
Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst (2006) 2.16
Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med (2003) 2.16
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12
Cervical cancers after human papillomavirus vaccination. Obstet Gynecol (2009) 2.11
Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec (2009) 2.11
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics (2005) 1.94
Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis (2008) 1.93
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine (2009) 1.92
Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis (2004) 1.87
HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med (2009) 1.87
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health (2007) 1.63
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine (2007) 1.53
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther (2003) 1.45
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine (2008) 1.35
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer (2007) 1.30
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine (2008) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
The epidemiology of cervical cancer. Cancer J (2003) 1.20
Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol (2002) 1.14
An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol (2004) 1.13
Human papillomavirus and molecular considerations for cancer risk. Cancer (2008) 1.12
Human papillomavirus vaccine should be given before sexual debut for maximum benefit. J Infect Dis (2007) 1.11
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 1.05
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med (2010) 1.03
Human papillomavirus infection: a concise review of natural history. Obstet Gynecol (2009) 1.02
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine (2008) 1.01
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol (2005) 1.00
Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther (2008) 1.00
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol (2009) 0.98
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des (2005) 0.98
Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target (2005) 0.95
The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol (2005) 0.95
Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol (2003) 0.94
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol (2005) 0.93
Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine (2008) 0.92
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res (2010) 0.90
Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine (2003) 0.89
Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol (2000) 0.88
Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine (2009) 0.86
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health (2010) 0.86
Policy statement--Recommended childhood and adolescent immunization schedules--United States, 2010. Pediatrics (2010) 0.84
Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus. Cancer J (2011) 0.80
Risk of residual invasive disease in women with microinvasive squamous cancer in a conization specimen. Obstet Gynecol (1997) 0.80
Human papillomavirus (HPV) vaccine: a position statement of the Society for Adolescent Medicine. J Adolesc Health (2006) 0.79
Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int J Oncol (2008) 0.77
Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol (1998) 0.75
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther (2010) 1.93
Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. Am J Hum Genet (2004) 1.87
FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics (2005) 1.70
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther (2011) 1.51
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 1.41
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One (2012) 1.38
Disruption of Contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. Am J Hum Genet (2008) 1.31
The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol (2002) 1.30
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood (2003) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets (2007) 1.26
The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol (2013) 1.20
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate (2009) 1.19
In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res (2007) 1.16
Nanotechnology and human health: risks and benefits. J Appl Toxicol (2010) 1.15
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12
Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol (2002) 1.12
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate (2011) 1.11
AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol (2008) 1.11
Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res (2003) 1.11
Simultaneous analysis and quality assurance for diffusion tensor imaging. PLoS One (2013) 1.07
Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol (2011) 1.06
Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep (2013) 1.06
p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol (2010) 1.06
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06
A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol (2009) 1.05
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med (2007) 1.05
Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol (2005) 1.03
Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol (2007) 1.02
Two cases of post-coital vaginal cuff dehiscence with small bowel evisceration after robotic-assisted laparoscopic hysterectomy. Int J Surg Case Rep (2013) 1.02
Cancer: looking for simplicity and finding complexity. Cancer Cell Int (2006) 1.01
The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol (2011) 1.01
HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol (2003) 0.99
Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood (2002) 0.98
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol (2009) 0.98
Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem (2004) 0.96
The complexity of anatomical systems. Theor Biol Med Model (2005) 0.96
Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95
The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res (2002) 0.95
Mapping gene expression patterns during myeloid differentiation using the EML hematopoietic progenitor cell line. Exp Hematol (2002) 0.94
Abdominal wall port site metastasis after robotically staged endometrial carcinoma: A case report. Int J Surg Case Rep (2013) 0.94
CD4+ T cell matters in tumor immunity. Int Rev Immunol (2003) 0.93
Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity (2010) 0.93
Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol (2011) 0.93
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol (2003) 0.93
Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer (2006) 0.93
Sigmoid plasmacytoma mimicking colon cancer in a patient with multiple myeloma: case report and review of literature. Gastrointest Endosc (2009) 0.93
Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells. Carcinogenesis (2009) 0.92
Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer (2005) 0.92
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
Ins and outs of clinical trials with peptide-based vaccines. Front Biosci (2002) 0.91
Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol (2002) 0.91
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res (2002) 0.91
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1. Bioorg Med Chem Lett (2010) 0.90
Expression, purification, and characterization of recombinant human transferrin from rice (Oryza sativa L.). Protein Expr Purif (2010) 0.90
Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther (2011) 0.90
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res (2010) 0.90
Infection, replication, and cytopathology of human papillomavirus type 31 in trophoblasts. Virology (2003) 0.89
Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim (2006) 0.89
Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer (2005) 0.89
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One (2010) 0.89
Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene (2004) 0.89
Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol (2006) 0.89
A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res (2012) 0.89
Stemmed implants improve stability in augmented constrained condylar knees. Clin Orthop Relat Res (2008) 0.89
Emerging strategies in tumor vaccines. Curr Opin Oncol (2002) 0.89
Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin. Surg Today (2008) 0.89
Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol (2007) 0.89